NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) today reported financial results for the third quarter and first nine-month period of fiscal year 2007. The Company reported a net loss of $5.3 million, or $.07 per share, for the third quarter of 2007 compared to a net loss of $5.5 million, or $.07 per share, for the third quarter of 2006. For the nine months ended September 30, 2007, AVANT reported a net loss of $16.4 million, or $.22 per share, compared to a net loss of $14.2 million, or $.19 per share, for the nine months ended September 30, 2006. The 2007 nine month losses include one-time restructuring charges of $765,204. AVANT reported cash and cash equivalents of $20.3 million at September 30, 2007.
